Downregulation of CD40 expression contributes to the accumulation of myeloid‑derived suppressor cells in gastric tumors

Shen,Jin; Chen,Xiaojuan; Wang,Zhenxing; Zhang,Guangbo; Chen,Weichang

doi:10.3892/ol.2014.2174

Downregulation of CD40 expression contributes to the accumulation of myeloid‑derived suppressor cells in gastric tumors

Authors:
- Jin Shen
- Xiaojuan Chen
- Zhenxing Wang
- Guangbo Zhang
- Weichang Chen
View Affiliations

Affiliations: Department of Gastroenterology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China , Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, Jiangsu 215006, P.R. China
Published online on: May 26, 2014 https://doi.org/10.3892/ol.2014.2174
Pages: 775-780

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

An elevated number of myeloid‑derived suppressor cells (MDSCs) in tumor‑bearing hosts has been recognized as a crucial mediator of tumor progression due to the cells potent ability to suppress antitumor immunity. Cluster of differentiation (CD) 40, as a suppressive phenotype expressed in MDSCs, is essential for MDSC‑mediated immune suppression and the expansion of T regulatory cells. However, whether CD40 exerts a direct effect on the accumulation of MDSCs remains unclear. In the present study, CD40 was observed to be highly expressed on the MDSCs obtained from mice bearing gastric tumors. Notably, a significant decrease in the level of CD40 expression was observed in addition to an increased number of MDSCs during tumor progression. Further analysis revealed that the MDSC levels were found to positively correlate with tumor progression and that CD40 expression levels inversely correlate with the accumulation of MDSCs. To confirm the potent correlation between CD40 expression and the accumulation of MDSCs, the apoptosis of the MDSCs was detected using agonistic anti‑CD40 treatment. The results indicated that CD40 activation induces apoptosis in MDSCs and that the downregulation of CD40 expression may contribute to MDSC accumulation by facilitating MDSC resistance to apoptosis. Thus, these observations provide a novel mechanism to improve our understanding of the involvement of CD40 in MDSC accumulation during cancer development.

View Figures

View References

1	Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 9:162–174. 2009.
2	Yang L, DeBusk LM, Fukuda K, Fingleton B, Green-Jarvis B, Shyr Y, Matrisian LM, Carbone DP and Lin PC: Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell. 6:409–421. 2004.
3	Ostrand-Rosenberg S and Sinha P: Myeloid-derived suppressor cells: linking inflammation and cancer. J Immunol. 182:4499–4506. 2009.
4	Yang R, Cai Z, Zhang Y, Yutzy WH IV, Roby KF and Roden RB: CD80 in immune suppression by mouse ovarian carcinoma-associated Gr-1+CD11b+ myeloid cells. Cancer Res. 66:6807–6815. 2006.
5	Huang B, Pan PY, Li Q, Sato AI, Levy DE, Bromberg J, Divino CM and Chen SH: Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res. 66:1123–1131. 2006.
6	Serafini P, Mgebroff S, Noonan K and Borrello I: Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T Cells. Cancer Res. 68:5439–5449. 2008.
7	Greenwald RJ, Freeman GJ and Sharpe AH: The B7 family revisited. Annu Rev Immunol. 23:515–548. 2005.
8	Pan PY, Ma G, Weber KJ, Ozao-Choy J, Wang G, Yin B, Divino CM and Chen SH: Immune stimulatory receptor CD40 is required for T-cell suppression and T regulatory cell activation mediated by myeloid-derived suppressor cells in cancer. Cancer Res. 70:99–108. 2010.
9	Sinha P, Chornoguz O, Clements VK, Artemenko KA, Zubarev RA and Ostrand-Rosenberg S: Myeloid-derived suppressor cells express the death receptor Fas and apoptose in response to T cell-expressed FasL. Blood. 117:5381–5390. 2011.
10	Rizvi M, Pathak D, Freedman JE and Chakrabarti S: CD40-CD40 ligand interactions in oxidative stress, inflammation and vascular disease. Trends Mol Med. 14:530–538. 2008.
11	Van Kooten C and Banchereau J: CD40-CD40 ligand. J Leukoc Biol. 67:2–17. 2000.
12	Murugaiyan G, Martin S and Saha B: CD40-induced countercurrent conduits for tumor escape or elimination? Trends Immunol. 28:467–473. 2007.
13	Schlom J, Jochems C, Gulley JL and Huang J: The role of soluble CD40L in immunosuppression. Oncoimmunology. 2:e225462013.
14	Huang J, Jochems C, Talaie T, Anderson A, Jales A, Tsang KY, Madan RA, Gulley JL and Schlom J: Elevated serum soluble CD40 ligand in cancer patients may play an immunosuppressive role. Blood. 120:3030–3038. 2012.
15	Roth F, De La Fuente AC, Vella JL, Zoso A, Inverardi L and Serafini P: Aptamer-mediated blockade of IL4Rα triggers apoptosis of MDSCs and limits tumor progression. Cancer Res. 72:1373–1383. 2012.
16	Ribechini E, Leenen PJ and Lutz MB: Gr-1 antibody induces STAT signaling, macrophage marker expression and abrogation of myeloid-derived suppressor cell activity in BM cells. Eur J Immunol. 39:3538–3551. 2009.
17	Vincent J, Mignot G, Chalmin F, Ladoire S, Bruchard M, Chevriaux A, Martin F, Apetoh L, Rébé C and Ghiringhelli F: 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity. Cancer Res. 70:3052–3061. 2010.
18	Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG and Hegmans JP: COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer. 10:4642010.
19	Weiss JM, Back TC, Scarzello AJ, Subleski JJ, Hall VL, Stauffer JK, Chen X, Micic D, Alderson K, Murphy WJ and Wiltrout RH: Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci USA. 106:19455–19460. 2009.
20	Zhao X, Rong L, Zhao X, Li X, Liu X, Deng J, Wu H, Xu X, Erben U, Wu P, et al: TNF signaling drives myeloid-derived suppressor cell accumulation. J Clin Invest. 122:4094–4104. 2012.
21	Youn JI, Nagaraj S, Collazo M and Gabrilovich DI: Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol. 181:5791–5802. 2008.
22	Ostrand-Rosenberg S, Sinha P, Chornoguz O and Ecker C: Regulating the suppressors: apoptosis and inflammation govern the survival of tumor-induced myeloid-derived suppressor cells (MDSC). Cancer Immunol Immunother. 61:1319–1325. 2012.
23	Humphreys EH, Williams KT, Adams DH and Afford SC: Primary and malignant cholangiocytes undergo CD40 mediated Fas dependent apoptosis, but are insensitive to direct activation with exogenous Fas ligand. PLoS One. 5:e140372010.
24	Yu H, Pardoll D and Jove R: STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer. 9:798–809. 2009.
25	Ahmed-Choudhury J, Williams KT, Young LS, Adams DH and Afford SC: CD40 mediated human cholangiocyte apoptosis requires JAK2 dependent activation of STAT3 in addition to activation of JNK1/2 and ERK1/2. Cell Signal. 18:456–468. 2006.